Search alternatives:
significant case » significant cause (Expand Search), significant based (Expand Search), significant change (Expand Search)
mean decrease » a decrease (Expand Search)
new decrease » nn decrease (Expand Search), we decrease (Expand Search), teer decrease (Expand Search)
case based » made based (Expand Search), game based (Expand Search), rate based (Expand Search)
significant case » significant cause (Expand Search), significant based (Expand Search), significant change (Expand Search)
mean decrease » a decrease (Expand Search)
new decrease » nn decrease (Expand Search), we decrease (Expand Search), teer decrease (Expand Search)
case based » made based (Expand Search), game based (Expand Search), rate based (Expand Search)
-
141
Deterministic result of the base-case analysis.
Published 2024“…Efficacy data and baseline characteristics in the base-case analysis were primarily derived from the 11-year results of the HERA trial. …”
-
142
-
143
Mean platelet volume and neutrophil to lymphocyte ratio decrease in patients with depression with antidepressant treatment
Published 2022“…When we look at admission and discharge scores of clinical scales, decrement is statistically significant for both HAM-D and CGI-S. There was decline both in MPV and NLR which were both statistically significant. …”
-
144
-
145
-
146
-
147
-
148
-
149
-
150
-
151
Synaptopathy at IHC-SGN synapses decreases the peak of the CAP significantly, without changes to peak latency and width.
Published 2021“…Shaded regions correspond to the standard error of the mean and dashed lines correspond to the peaks of each CAP, labeled with the same colors as the CAPs. …”
-
152
-
153
-
154
-
155
The base case analysis.
Published 2025“…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …”
-
156
-
157
Base-case results.
Published 2025“…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …”
-
158
-
159
-
160